Claims
- 1. Isolated CD2BP2 protein, or an active derivative or fragment thereof having CD2BP2 protein activity.
- 2. Isolated CD2BP2 protein of claim 1, wherein said protein is a derivative possessing substantial sequence identity with SEQ ID NO: 2.
- 3. Isolated CD2BP2 protein of claim 1, wherein the protein has the amino acid sequence of SEQ ID NO: 2.
- 4. Isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO:3.
- 5. Isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO: 9.
- 6. Isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO: 10.
- 7. Isolated nucleic acid molecule which encodes a CD2BP2 protein, or an active derivative or fragment of said protein having CD2BP2 protein activity, or the complement of said nucleic acid molecule.
- 8. Isolated nucleic acid molecule of claim 7, wherein the CD2BP2 protein is a derivative possessing substantial sequence identity with SEQ ID NO: 2.
- 9. Isolated nucleic acid molecule of claim 7, wherein said nucleic acid molecule has the same nucleotide sequence as the endogenous gene encoding a CD2BP2 protein.
- 10. Isolated nucleic acid molecule of claim 7, wherein said nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 1.
- 11. Isolated nucleic acid molecule consisting essentially of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3.
- 12. Isolated nucleic acid molecule consisting essentially of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 9.
- 13. Isolated nucleic acid molecule consisting essentially of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 10.
- 14. A nucleic acid construct comprising the isolated nucleic acid molecule of claim 7 operably linked to a regulatory sequence.
- 15. A nucleic acid construct comprising the isolated nucleic acid molecule of claim 11 operably linked to a regulatory sequence.
- 16. A nucleic acid construct comprising the isolated nucleic acid molecule of claim 12 operably linked to a regulatory sequence.
- 17. A nucleic acid construct comprising the isolated nucleic acid molecule of claim 13 operably linked to a regulatory sequence.
- 18. A recombinant host cell comprising the nucleic acid construct of claim 14.
- 19. A recombinant host cell comprising the nucleic acid construct of claim 15.
- 20. A recombinant host cell comprising the nucleic acid construct of claim 16.
- 21. A recombinant host cell comprising the nucleic acid construct of claim 17.
- 22. A method for preparing a CD2BP2 protein, or an active derivative of fragment thereof, comprising culturing the recombinant host cell of claim 18.
- 23. An antibody which selectively binds to isolated CD2BP2 protein, or to an active derivative or fragment thereof.
- 24. An antibody of claim 23, wherein the isolated CD2BP2 protein has the amino acid sequence of SEQ ID NO: 2.
- 25. A method for assaying the presence of CD2BP2 protein in a cell, comprising contacting said cell with an antibody of claim 23.
- 26. The method of claim 25, wherein said cell is in a tissue sample.
- 27. An assay for identifying an agent which inhibits activity of CD2BP2 protein, comprising the steps of:
(a) contacting a composition comprising the CD2BP2 protein, or an active derivative or fragment thereof, with an agent to be tested; and (b) identifying inhibition of CD2BP2 protein activity.
- 28. A novel agent which inhibits activity of CD2BP2 protein identified according to the assay of claim 27.
- 29. A method of inhibiting CD2BP2 protein activity, comprising contacting said CD2BP2 protein with an agent that inhibits activity of the CD2BP2 protein.
- 30. An assay for identifying an agent which enhances activity of CD2BP2 protein, comprising the steps of:
(a) contacting a composition comprising the CD2BP2 protein, or an active derivative or fragment thereof, with an agent to be tested; and (b) identifying enhancement of CD2BP2 protein activity.
- 31. A novel agent which enhances CD2BP2 protein activity identified according to the assay of claim 30.
- 32. A method of enhancing the activity of CD2BP2 protein, comprising contacting said CD2BP2 protein with an agent that enhances activity of the CD2BP2 protein.
- 33. A method of identifying an agent which modulates signal transduction or cell adhesion, comprising the steps of:
(a) contacting a composition comprising the CD2BP2 protein, or an active derivative or fragment thereof, with an agent to be tested; and (b) identifying modulation of CD2BP2 protein activity, wherein the presence of modulation of CD2BP2 protein activity indicates that the agent modulates signal transduction or cell adhesion.
- 34. A method of modulating signal transduction or cell adhesion, comprising contacting CD2BP2 protein with an agent that modulates CD2BP2 protein activity.
- 35. An assay for identifying an agent which enhances CD2-triggered IL-2 production, comprising the steps of:
(a) contacting a composition comprising the CD2BP2 protein, or an active derivative or fragment thereof, with an agent to be tested; and (b) identifying enhancement of IL-2 production.
- 36. A novel agent which enhances CD2-triggered IL-2 production identified according to the assay of claim 30.
- 37. A method of enhancing CD2-triggered IL-2 production, comprising contacting a cell comprising CD2BP2 protein with an agent that enhances CD2-triggered IL-2 production.
- 38. A method according to claim 37, wherein the agent is selected from the group consisting of CD2BP2, or an active derivative or fragment thereof having CD2BP2 activity, and a nucleic acid molecule comprising a nucleic acid sequence encoding CD2BP2 or an active derivative or fragment thereof having CD2BP2 activity.
- 39. An assay for identifying an agent which inhibits CD2-triggered IL-2 production, comprising the steps of:
(a) contacting a composition comprising the CD2BP2 protein, or an active derivative or fragment thereof, with an agent to be tested; and (b) identifying inhibition of IL-2 production.
- 40. A novel agent which inhibits CD2-triggered IL-2 production identified according to the assay of claim 39.
- 41. A method of inhibiting CD2-triggered IL-2 production, comprising contacting a cell comprising CD2BP2 protein with an agent that inhibits CD2-triggered IL-2 production.
- 42. A method according to claim 41, wherein the agent is a nucleic acid molecule comprising a nucleic acid sequence encoding the complement of CD2BP2 or an active derivative or fragment thereof having CD2BP2 activity.
- 43. A method of targeting an agent to a CD2 molecule in a cell, comprising linking the agent with CD2BP2 protein or an active derivative or fragment thereof having CDBP2 activity.
- 44. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3, wherein said nucleic acid molecule does not naturally comprise said nucleotide sequence.
- 45. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 9, wherein said nucleic acid molecule does not naturally comprise said nucleotide sequence.
- 46. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 10, wherein said nucleic acid molecule does not naturally comprise said nucleotide sequence.
- 47. An isolated protein encoded by the nucleic acid molecule according to claim 44.
- 48. An isolated protein encoded by the nucleic acid molecule according to claim 45.
- 49. An isolated protein encoded by the nucleic acid molecule according to claim 46.
- 50. A method of enhancing protein-protein interactions, comprising contacting a protein encoded by an isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3, wherein said nucleic acid molecule does not naturally comprise said nucleotide sequence, with a protein encoded by an isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 10, wherein said nucleic acid molecule does not naturally comprise said nucleotide sequence.
- 51. A method of enhancing protein-protein interactions, comprising contacting a protein encoded by an isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 9, wherein said nucleic acid molecule does not naturally comprise said nucleotide sequence, with a protein encoded by an isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 10, wherein said nucleic acid molecule does not naturally comprise said nucleotide sequence.
- 52. A method of enhancing protein-protein interactions, comprising contacting a protein comprising the amino acid sequence of SEQ ID NO: 3, wherein said protein does not naturally comprise said amino acid sequence, with a protein comprising the amino acid sequence of SEQ ID NO:10, wherein said protein does not naturally comprise said amino acid sequence.
- 53. A method of enhancing protein-protein interactions, comprising contacting a protein comprising the amino acid sequence of SEQ ID NO: 9, wherein said protein does not naturally comprise said amino acid sequence, with a protein comprising the amino acid sequence of SEQ ID NO: 10, wherein said protein does not naturally comprise said amino acid sequence.
RELATED APPLICATIONS
[0001] This application is a continuation of International Application No. PCT/US99/26993 which designated the United States and was filed on Nov. 15, 1999, published in English, which claims the benefit of U.S. Provisional Application No. 60/111,007, filed Dec. 4, 1998 and No. 60/115,647, filed Jan. 13, 1999, the entire contents of which are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60111007 |
Dec 1998 |
US |
|
60115647 |
Jan 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US99/26993 |
Nov 1999 |
US |
Child |
09873106 |
Jun 2001 |
US |